Neogenomics (NEO) PT Lowered to $17 at BTIG

Neogenomics (NEO) PT Lowered to $17 at Morgan Stanley

Morgan Stanley analyst Tejas Savant lowered the price target on Neogenomics (NASDAQ: NEO) to $17.00 (from $18.00) while maintaining a Equalweight rating.

The analyst comments "Surprising albeit small miss on pharma budget flush spoils long track record of beats/raises; 25 guide/LRP in line w/ Jan prelim;... More

Neogenomics (NEO) PT Lowered to $18 at Jefferies

Jefferies analyst Tycho Peterson lowered the price target on Neogenomics (NASDAQ: NEO) to $18.00 (from $22.00) while maintaining a Buy rating.... More

Neogenomics (NEO) PT Lowered to $18 at Needham

Needham analyst Mike Matson lowered the price target on Neogenomics (NASDAQ: NEO) to $18.00 (from $19.00) while maintaining a Buy rating.

The analyst comments "NEO's 4Q24 revenue missed, while its EBITDA beat consensus. Management reiterated their 2025 revenue and EBITDA guidance. Revenue growth was... More

Raymond James Reiterates Market Perform Rating on Neogenomics (NEO)

Raymond James analyst Andrew Cooper reiterated a Market Perform on Neogenomics (NASDAQ: NEO).

The analyst comments "Quick take: This morning NeoGenomics reported 4Q results with the top line roughly 70 bp below consensus and nearly 200 bp below our view. With Clinical Services and Advanced Diagnostics now combined into one segment, visibility is lessened, but we estimate the former roughly matched consensus while... More

NeoGenomics (NEO) Tops Q4 EPS by 1c; offers guidance

NeoGenomics (NASDAQ: NEO) reported Q4 EPS of $0.04, $0.01 better than the analyst estimate of $0.03. Revenue for the quarter came in at $172 million versus the consensus estimate of $173.05 million.

GUIDANCE:

NeoGenomics sees FY2025 revenue of $735-745 million, versus the consensus of $735... More